Literature DB >> 16229960

Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis?

Janusz Rak1.   

Abstract

Cancer stem cells are presently viewed as carriers of the growth initiating potential, repopulation capability and drug resistance in tumors. However, many of these fundamental properties of cancer are host-related, modified by cell-cell interactions and/or dependent on angiogenesis. Indeed, it is well established that co-injection of cancer cells with their irradiated (mitotically dead) counterparts, or with Matrigel can significantly increase their tumor forming capacity (i.e. the attribute presently associated with cancer cell 'stemness'). Similarly transfection of angiogenic factors (e.g., VEGF/VPF) can promote such capacity in certain cell lines. Moreover, injection site (e.g., orthotopic vs. ectopic) may significantly modulate tumor take in experimental settings. These observations cannot be reconciled with the paradigm that tumor initiation potential is a fixed, constitutive and cell autonomous feature of a subset of cancer cells expressing stem cell markers (e.g., CD133, Sca1 and other). Instead, it is proposed here that 'stemness' in cancer (perhaps unlike in normal self renewing tissues), rather then being assigned to a particular readily identifiable cell subset, could be a property of interactive clusters of cancer cells (perhaps including, but not limited to cells with stem cell markers). Such 'multicellular units' would become equipped with properties experimentally perceived as 'stemness', i.e. the capacity to initiate tumor growth, when they express the capacity to induce angiogenesis. It is also postulated here that, while the pursuit of subsets of cancer cells harbouring stem cell markers has been fascinating and revealing, due to aforementioned limitations of the present stem cell concept and presumed intractability (e.g., mutability) of such cells, further therapeutic promise may reside in a better definition of 'multicellular angiogenic cancer stem units'.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16229960     DOI: 10.1016/j.mehy.2005.09.004

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

Review 1.  CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.

Authors:  Xueqing Sun; Guangcun Cheng; Mingang Hao; Jianghua Zheng; Xiaoming Zhou; Jian Zhang; Russell S Taichman; Kenneth J Pienta; Jianhua Wang
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

Review 2.  Enrichment of cancer stem cells based on heterogeneity of invasiveness.

Authors:  Shi-cang Yu; Xiu-wu Bian
Journal:  Stem Cell Rev Rep       Date:  2008-12-19       Impact factor: 5.739

Review 3.  Extracellular Vesicles in Brain Tumor Progression.

Authors:  Esterina D'Asti; Shilpa Chennakrishnaiah; Tae Hoon Lee; Janusz Rak
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

4.  Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer.

Authors:  Janusz Rak
Journal:  Front Pharmacol       Date:  2013-03-06       Impact factor: 5.810

5.  Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin.

Authors:  Lalita A Shevde; Brandon J Metge; Aparna Mitra; Yaguang Xi; Jingfang Ju; Judy A King; Rajeev S Samant
Journal:  J Cell Mol Med       Date:  2009-06-16       Impact factor: 5.310

Review 6.  Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds.

Authors:  Ming Hong; Hor Yue Tan; Sha Li; Fan Cheung; Ning Wang; Tadashi Nagamatsu; Yibin Feng
Journal:  Int J Mol Sci       Date:  2016-06-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.